Looking for a career in health economics and real-world evidence (RWE)? Check out the latest job openings in the pharmaceutical industry. There are many new opportunities available for RWE analysts, real-world evidence scientists, RWE managers, and real-world evidence market access managers in both pharmaceutical and life science consulting companies.
London, UK / Wavre, Belgium. The role of Senior Director, Global Real-World Evidence & Health Outcomes Research Lead is critical to achieving this ambition by ensuring that each medicine GSK brings to market is supported by scientifically credible, high-quality evidence that drives competitiveness and strong evidence-based product positioning, value propositions and value-based pricing. The role is essential for the alignment … Read more
Oeiras, Portugal. Working with other team members you will: *This position requires some degree of travel within Portugal (20% FTE). Our desired profile: Experience: Personal Skills and Behaviors: Education Requirements: IQVIA is the world leader in the provision of health and pharmaceutical data to the health care sector. Our Real-World Solutions department is globally renowned for providing business focused research, … Read more
Home-based, TX, US. Are you looking to make a difference in a patient’s life? At Cencora, you will find an innovative culture that is patient focused and dedicated to making a difference. What you will be doing… Cencora is excited to offer students the opportunity to apply for a paid ten-week virtual summer internship that is focused on applying your … Read more
Whippany, NJ, US. Evidence Generation, RWD/RWE & Behavioral Science has the objective to improve the health and consumer well-being through generating innovative and impactful evidence that is one of the foundations of our self-care business. The RWE Lead is responsible to deliver RWE strategies, initiatives and studies including leveraging complex, clinically rich, patient-level healthcare data to answer specific research questions … Read more
Mettawa, IL / Florham Park, NJ, US. The Associate Director, Market Access Marketing – VRAYLAR, will be responsible for the development and execution of US Market Access strategies and tactics for VRAYLAR, an oral atypical antipsychotic indicated for several mental health disorders. Working as a member of AbbVie’s US Market Access organization, this individual will lead strategies and tactics related … Read more
Budapest, Hungary. The Real-World Evidence (RWE) Investigator is an important scientific position responsible for supporting the development, coordination and execution of cutting-edge, effective, and efficient real world evidence strategy for drug and enablement projects at global level or for key critical markets. You will work in close partnership with the global RWE Strategy Therapeutic Area Lead to develop consensus among … Read more
Paris, France / Barcelona, Spain. Health Economics and Market Access Department: We have a worldwide presence ensuring key market expertise and efficiency in delivery. We have offices in Montreal, Toronto, London, Paris, Barcelona, Sofia & Shanghai. We are a diverse team of 15 different nationalities. We offer services for 5 major activities: Evidence review and Value Communication, Strategic Market Access, … Read more
Boston, MA, US. The Real World Evidence Director leads the successful execution of studies in accordance with RWE, Disease area, Program and Enterprise goals as well as ensuring the reliable tracking and reporting of RWE studies, analyses and resource use. As an integral member of the RWE team, the RWE Director leverages subject matter expertise in their disease portfolio to … Read more
London, UK. As part of the wider Real-World Evidence (RWE) team Lumanity is currently building a RWE Data Luminary Consulting Practice. This practice has been started as our clients have unique challenges which require RWE. For example, understanding treatment patterns/patient journeys, drug utilization studies, effectiveness of standard of care/generating synthetic controls, outcomes research, cost of illness, burden of disease, and … Read more
Europe. We are seeking highly qualified candidates to fill the position: European Health Economics Outcomes Research & Real World Evidence Senior Manager Oncology (m/f/x). The Position: The Senior Manager HEOR & RWE leads the development of the European HEOR and RWE strategy for the product(s) he/she is responsible for, in order to maximize the outcomes in terms of Market Access … Read more
Dublin, Ireland / Home-based, UK. GBS is the unique trusted network of specialists partnering across all of Novartis delivering high quality services and innovative solutions to enable our enterprise goal of reimagining medicine. The Associate Director will support RWE Executive Directors in developing and executing RWE strategies for molecules within a disease area as well as the execution of Real … Read more
Hyderabad, India. Main responsibilities: Use statistical, analytical, data management and computational skills to execute analyses of pre-existing data to investigate research questions in teamwork with colleagues from health economics and value assessment (HEVA), medical affairs, business operations & strategy (BO&S) and commercial product teams; Work together with these SGz functions and the RWE group located in the Chief Digital Office … Read more
Milan, Italy. As a Value & Access Manager Oncology in Italy, you will play a pivotal role in channeling our scientific capabilities to make a positive impact on changing patients’ lives. Market Access has a key role to ensure that the medicines are made available locally and most importantly that these medicines are reimbursed and made available to patients who need them. … Read more
London, UK / Upper Providence, PA, US. The role of Senior Director, Global Real-World Evidence & Health Outcomes Research Lead is critical to achieving this ambition by ensuring that each medicine GSK brings to market is supported by scientifically credible, high-quality evidence that drives competitiveness and strong evidence-based product positioning, value propositions and value-based pricing. The role is essential for … Read more
Home-based, UK. Cencora has an ongoing need for an experienced Health Economic Modeler to join its Market Access and Healthcare Consulting team based in Europe. This is a remote opportunity based in the United Kingdom. Please apply if you are interested in being considered for full-time opportunities to join our team and support in the listed areas below: Position … Read more
Real-World Evidence in Health Economics
Real-world evidence (RWE) has become an increasingly important aspect of health economics research in recent years. It provides a comprehensive and in-depth understanding of how different health interventions work in real-world settings.
What is Real-World Evidence?
Real-world evidence (RWE) is defined as data collected from sources other than traditional randomized controlled trials (RCTs). These data come from a variety of sources, including electronic health records (EHRs), claims databases, registries, patient-reported outcomes (PROs), and surveys.
RWE allows researchers to evaluate the effectiveness, safety, and cost-effectiveness of health interventions in real-world settings. This is important because RCTs often have strict inclusion and exclusion criteria, which means that the results may not be generalizable to real-world populations.
Importance of Real-World Evidence in Health Economics
RWE is becoming increasingly important in health economics because it provides a more complete picture of the effectiveness and safety of health interventions. By using RWE, researchers can evaluate how interventions work in a variety of settings and patient populations, which can help inform clinical practice and policy decisions.
RWE can also be used to conduct cost-effectiveness analyses, which help policymakers determine the value of health interventions. Cost-effectiveness analyses compare the costs and benefits of different health interventions, taking into account the costs of the intervention as well as the costs of any adverse events or complications that may occur.
Differences between RWE and Randomized Controlled Trials (RCTs)
RCTs are considered the gold standard for evaluating the effectiveness and safety of health interventions. However, there are several key differences between RWE and RCTs.
RCTs are conducted under controlled conditions and have strict inclusion and exclusion criteria, which means that the results may not be generalizable to real-world populations. RWE, on the other hand, is collected from a variety of sources and reflects the real-world experiences of patients.
RCTs also tend to be shorter in duration than RWE studies, which means that they may not capture the long-term effects of health interventions. RWE studies, on the other hand, can provide information on the long-term effectiveness and safety of interventions.
Methods of Collecting RWE
There are several methods of collecting RWE, including:
Electronic Health Records (EHRs) EHRs are digital records of patient health information that are maintained by healthcare providers. EHRs can provide a wealth of information on patient demographics, diagnoses, treatments, and outcomes.
Claims Databases Claims databases contain information on healthcare services and medications that are billed to insurance providers. Claims data can provide information on healthcare utilization, costs, and outcomes.
Registries Registries are databases that collect information on specific diseases or health conditions. They can provide valuable information on disease prevalence, treatment patterns, and outcomes.
Patient-Reported Outcomes (PROs) PROs are questionnaires or surveys completed by patients that assess their health status, symptoms, and quality of life. PROs can provide information on patient preferences and experiences with different interventions.
Surveys Surveys can be used to collect information on patient demographics, health behaviors, and healthcare utilization. They can also be used to assess patient preferences and satisfaction with different interventions.
Advantages of Real-World Evidence
There are several advantages of using RWE in health economics research, including:
RWE reflects real-world experiences and can provide a more comprehensive understanding of the effectiveness and safety of interventions.
RWE can be used to evaluate interventions in a variety of settings and patient populations.
RWE can provide information on the long-term effectiveness and safety of interventions.
RWE can be used to conduct cost-effectiveness analyses, which can inform clinical practice and policy decisions.
Challenges and Limitations of Real-World Evidence
There are several challenges and limitations to using RWE in health economics research, including:
RWE can be subject to bias and confounding, which can affect the validity of the results.
RWE can be difficult to collect and analyze, particularly when using multiple data sources.
RWE may not be as well-suited for evaluating rare diseases or interventions.
Applications of Real-World Evidence
RWE has several applications in health economics research, including:
Health Technology Assessment Health technology assessment (HTA) is a process that evaluates the clinical effectiveness, safety, and cost-effectiveness of new health technologies. RWE can be used in HTA to provide information on the real-world effectiveness and safety of interventions.
Comparative Effectiveness Research Comparative effectiveness research (CER) compares the effectiveness of different interventions for the same health condition. RWE can be used in CER to compare the effectiveness of interventions in different patient populations and settings.
Post-Marketing Surveillance Post-marketing surveillance is the process of monitoring the safety and effectiveness of new drugs and medical devices after they have been approved for use. RWE can be used in post-marketing surveillance to monitor the long-term safety and effectiveness of interventions.
Future of Real-World Evidence in Health Economics
RWE is likely to become increasingly important in health economics research in the future. Advances in technology and data analytics are making it easier to collect and analyze RWE, and policymakers are recognizing the importance of using RWE to inform clinical practice and policy decisions.
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Toujours activé
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.